A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 16-27

  Cojoc, Monica ^a   Mäbert, Katrin ^a   Muders, Michael H ^a   Dubrovska, Anna ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Autophagy; Cancer stem cells; DNA repair; Hypoxia; Therapy resistance

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CHLOROQUINE PLUS HYDROXYCHLOROQUINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYCHLOROQUINE; IRINOTECAN; MITOXANTRONE; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; TUMOR MARKER;

AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84923248130     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.06.004     Document Type: Review

References (214)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(January (1)):11-30.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(März (5)):646-674.
3. Cillo C., Dick J.E., Ling V., Hill R.P. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res 1987, 47(May (10)):2604-2608.
4. Lee A.J.X., Endesfelder D., Rowan A.J., Walther A., Birkbak N.J., Futreal P.A., et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71(March (5)):1858-1870.
5. Beà S., Valdés-Mas R., Navarro A., Salaverria I., Martín-Garcia D., Jares P., et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013, 110(November (45)):18250-18255.
6. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
7. Hwang-Verslues W.W., Kuo W.-H., Chang P.-H., Pan C.-C., Wang H.-H., Tsai S.-T., et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS ONE 2009, 4(12):e8377.
8. Navin N., Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011, 3(5):31.
9. Notta F., Mullighan C.G., Wang J.C.Y., Poeppl A., Doulatov S., Phillips L.A., et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469(January (7330)):362-367.
10. Sottoriva A., Spiteri I., Piccirillo S.G.M., Touloumis A., Collins V.P., Marioni J.C., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013, 110(March (10)):4009-4014.
11. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M.K., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339(February (6119)):543-548.
12. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501(September (7467)):328-337.
13. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(July (7)):730-737.
14. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(February (6464)):645-648.
15. Peitzsch C., Kurth I., Kunz-Schughart L., Baumann M., Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013, 108(September (3)):378-387.
16. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14(3):275-291.
17. Kong Y., Yoshida S., Saito Y., Doi T., Nagatoshi Y., Fukata M., et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008, 22(6):1207-1213.
18. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456(7222):593-598.
19. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012, 22:457-472.
20. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
21. Chen T., Dent S.Y.R. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet 2014, 15(February (2)):93-106.
22. Sun L., Mathews L.A., Cabarcas S.M., Zhang X., Yang A., Zhang Y., et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells 2013, 31(August (8)):1454-1466.
23. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339(March (6127)):1567-1570.
24. Wend P., Fang L., Zhu Q., Schipper J.H., Loddenkemper C., Kosel F., et al. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. Embo J 2013, 32(July (14)):1977-1989.
25. Armstrong A.B., Wang M., Eble J.N., MacLennan G.T., Montironi R., Tan P.-H., et al. TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol Off J U S Can Acad Pathol Inc 2009, 22(January (1)):113-118.
26. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15(May (5)):559-565.
27. Zucchi I., Sanzone S., Astigiano S., Pelucchi P., Scotti M., Valsecchi V., et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci U S A 2007, 104(June (25)):10476-10481.
28. Golebiewska A., Brons N.H.C., Bjerkvig R., Niclou S.P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8(February (2)):136-147.
29. DeGorter M.K., Xia C.Q., Yang J.J., Kim R.B. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 2012, 52:249-273.
30. Mo W., Zhang J.-T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012, 3(1):1-27.
31. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(January (1)):48-58.
32. An Y., Ongkeko W.M. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 2009, 5(December (12)):1529-1542.
33. Vasiliou V., Vasiliou K., Nebert D.W. Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009, 3(April (3)):281-290.
34. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
35. Huang W.-C., Hsieh Y.-L., Hung C.-M., Chien P.-H., Chien Y.-F., Chen L.-C., et al. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLOS ONE 2013, 8(12):e83627.
36. Bleau A.-M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4(March (3)):226-235.
37. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005, 65(July (14)):6207-6219.
38. Lecerf-Schmidt F., Peres B., Valdameri G., Gauthier C., Winter E., Payen L., et al. ABCG2: recent discovery of potent and highly selective inhibitors. Future Med Chem 2013, 5(June (9)):1037-1045.
39. Stacy A.E., Jansson P.J., Richardson D.R. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 2013, 84(November (5)):655-669.
40. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7(June (2)):292-306.
41. Young S.Z., Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda, MD) 2009, 24(June):171-185.
42. Marcato P., Dean C.A., Giacomantonio C.A., Lee P.W.K. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle Georget Tex 2011, 10(May (9)):1378-1384.
43. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1(November (5)):555-567.
44. Li T., Su Y., Mei Y., Leng Q., Leng B., Liu Z., et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Investig J Tech Methods Pathol 2010, 90(February (2)):234-244.
45. Le Magnen C., Bubendorf L., Rentsch C.A., Mengus C., Gsponer J., Zellweger T., et al. Characterization and clinical relevance of ALDH bright populations in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2013, 19(October (19)):5361-5371.
46. Van den Hoogen C., van der Horst G., Cheung H., Buijs J.T., Lippitt J.M., Guzmán-Ramírez N., et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010, 70(June (12)):5163-5173.
47. Sullivan J.P., Spinola M., Dodge M., Raso M.G., Behrens C., Gao B., et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010, 70(December (23)):9937-9948.
48. Rasper M., Schäfer A., Piontek G., Teufel J., Brockhoff G., Ringel F., et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncol 2010, 12(October (10)):1024-1033.
49. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., La Noce M., et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J Off Publ Fed Am Soc Exp Biol 2013, 27(January (1)):13-24.
50. Singh S., Brocker C., Koppaka V., Chen Y., Jackson B.C., Matsumoto A., et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med 2013, 56(March):89-101.
51. Ajani J.A., Wang X., Song S., Suzuki A., Taketa T., Sudo K., et al. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol 2014, 8(February (1)):142-149.
52. Magni M., Shammah S., Schiró R., Mellado W., Dalla-Favera R., Gianni A.M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996, 87(February (3)):1097-1103.
53. Parajuli B., Fishel M.L., Hurley T.D. Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells. J Med Chem 2014, 57(January (2)):449-461.
54. Moreb J.S., Gabr A., Vartikar G.R., Gowda S., Zucali J.R., Mohuczy D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 2005, 312(January (1)):339-345.
55. Breitman T.R., Selonick S.E., Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980, 77(May (5)):2936-2940.
56. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72(August (2)):567-572.
57. Mi J.-Q., Li J.-M., Shen Z.-X., Chen S.-J., Chen Z. How to manage acute promyelocytic leukemia. Leukemia 2012, 26(August (8)):1743-1751.
58. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94(August (4)):1192-1200.
59. Fenaux P., Le Deley M.C., Castaigne S., Archimbaud E., Chomienne C., Link H., et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993, 82(December (11)):3241-3249.
60. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337(October (15)):1021-1028.
61. Formelli F., Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993, 53(November (22)):5374-5376.
62. + human breast cancer cells. Breast Cancer Res Treat 2012, 133(May (1)):75-87.
63. Grunt Th.W., Dittrich E., Offterdinger M., Schneider S.M., Dittrich C., Huber H. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 1998, 78(July (1)):79-87.
64. Pettersson F., Colston K.W., Dalgleish A.G. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001, 23(October (3)):273-279.
65. Kalemkerian G.P., Ou X. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 1999, 43(2):145-150.
66. Bertrand G., Maalouf M., Boivin A., Battiston-Montagne P., Beuve M., Levy A., et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev 2014, 10(February (1)):114-126.
67. Mu X., Isaac C., Greco N., Huard J., Weiss K. Notch signaling is associated with ALDH Activity and an aggressive metastatic phenotype in murine osteosarcoma cells. Front Oncol 2013, 3:143.
68. Mu X., Isaac C., Schott T., Huard J., Weiss K. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013, 2013:480713.
69. Moreb J.S., Baker H.V., Chang L.-J., Amaya M., Lopez M.C., Ostmark B., et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008, 7:87.
70. D'Addario C., Johansson S., Candeletti S., Romualdi P., Ögren S.O., Terenius L., et al. Ethanol and acetaldehyde exposure induces specific epigenetic modifications in the prodynorphin gene promoter in a human neuroblastoma cell line. FASEB J Off Publ Fed Am Soc Exp Biol 2011, 25(March (3)):1069-1075.
71. Tegeder I., Geisslinger G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev 2004, 56(September (3)):351-369.
72. Corominas-Faja B., Oliveras-Ferraros C., Cuyàs E., Segura-Carretero A., Joven J., Martin-Castillo B., et al. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle Georget Tex 2013, 12(November (21)):3390-3404.
73. Cheung-Ong K., Giaever G., Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol 2013, 20(May (5)):648-659.
74. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461(October (7267)):1071-1078.
75. Brandsma I., Gent D.C. Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr 2012, 3(1):9.
76. Thompson L.H. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 2012, 751(December (2)):158-246.
77. Li X., Heyer W-D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008, 18(January (1)):99-113.
78. Jasin M., Rothstein R. Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol 2013, 5(November (11)):a012740.
79. Jackson S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002, 23(May (5)):687-696.
80. Scully R., Xie A. Double strand break repair functions of histone H2AX. Mutat Res 2013, 750(October (1-2)):5-14.
81. Revet I., Feeney L., Bruguera S., Wilson W., Dong T.K., Oh D.H., et al. Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents. Proc Natl Acad Sci U S A 2011, 108(May (21)):8663-8667.
82. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(December (7120)):756-760.
83. Al-Assar O., Mantoni T., Lunardi S., Kingham G., Helleday T., Brunner T.B. Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2 fraction. Cancer Biol Ther 2011, 11(June (12)):1028-1035.
84. Chen Y., Li D., Wang D., Liu X., Yin N., Song Y., et al. Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells. J Cell Biochem 2012, 113(December (12)):3643-3652.
85. Lundholm L., Hååg P., Zong D., Juntti T., Mörk B., Lewensohn R., et al. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis 2013, 4:e478.
86. Kim S.-Y., Rhee J.G., Song X., Prochownik E.V., Spitz D.R., Lee Y.J. Breast cancer stem cell-like cells are more sensitive to ionizing radiation than non-stem cells: role of ATM. PLoS ONE 2012, 7(11):e50423.
87. Wang X., Ma Z., Xiao Z., Liu H., Dou Z., Feng X., et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep 2012, 28(December (6)):2247-2254.
88. Desai A., Webb B., Gerson S.L. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol J Eur Soc Ther Radiol Oncol 2014, (January).
89. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458(7239):780-783.
90. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007, 104(January (2)):618-623.
91. Zhang M., Behbod F., Atkinson R.L., Landis M.D., Kittrell F., Edwards D., et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68(June (12)):4674-4682.
92. Niida H., Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006, 21(January (1)):3-9.
93. Bartucci M., Svensson S., Romania P., Dattilo R., Patrizii M., Signore M., et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 2012, 19(May (5)):768-778.
94. Yin H., Glass J. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS ONE 2011, 6(9):e24080.
95. Gallmeier E., Hermann P.C., Mueller M.-T., Machado J.G., Ziesch A., De Toni E.N., et al. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. Stem Cells Dayt Ohio 2011, 29(March (3)):418-429.
96. Sena L.A., Chandel N.S. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012, 48(October (2)):158-167.
97. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8(July (7)):579-591.
98. Cook J.A., Gius D., Wink D.A., Krishna M.C., Russo A., Mitchell J.B. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004, 14(July (3)):259-266.
99. Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19(March (3)):387-400.
100. Smit J.K., Faber H., Niemantsverdriet M., Baanstra M., Bussink J., Hollema H., et al. Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013, 107(June (3)):434-441.
101. Koukourakis M.I., Giatromanolaki A., Tsakmaki V., Danielidis V., Sivridis E. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer 2012, 106(February (5)):846-853.
102. De Jong M.C., Pramana J., van der Wal J.E., Lacko M., Peutz-Kootstra C.J., de Jong J.M., et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2010, 16(November (21)):5329-5338.
103. Kroemer G., Mariño G., Levine B. Autophagy and the integrated stress response. Mol Cell 2010, 40(October (2)):280-293.
104. Rao R., Balusu R., Fiskus W., Mudunuru U., Venkannagari S., Chauhan L., et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012, 11(April (4)):973-983.
105. Gong C., Bauvy C., Tonelli G., Yue W., Deloménie C., Nicolas V., et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013, 32(May (18)). 2261-2272, 2272e.1-2272e.11.
106. Cho Y.-Y., Kim D.J., Lee H.S., Jeong C.-H., Cho E.-J., Kim M.-O., et al. Autophagy and cellular senescence mediated by Sox2 suppress malignancy of cancer cells. PLoS ONE 2013, 8(2):e57172.
107. Elzinga B.M., Nyhan M.J., Crowley L.C., O'Donovan T.R., Cahill M.R., McKenna S.L. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol 2013, 88(June (6)):455-462.
108. Galavotti S., Bartesaghi S., Faccenda D., Shaked-Rabi M., Sanzone S., McEvoy A., et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013, 32(February (6)):699-712.
109. Guan J.-L., Simon A.K., Prescott M., Menendez J.A., Liu F., Wang F., et al. Autophagy in stem cells. Autophagy 2013, 9(June (6)):830-849.
110. Sinclair A., Latif A.L., Holyoake T.L. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 2013, 169(August (8)):1693-1707.
111. Rausch V., Liu L., Apel A., Rettig T., Gladkich J., Labsch S., et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012, 227(July (3)):325-335.
112. Ma X.-H., Piao S.-F., Dey S., McAfee Q., Karakousis G., Villanueva J., et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 2014, 124(March (3)):1406-1417.
113. Nguyen H.G., Yang J.C., Kung H.-J., Shi X.-B., Tilki D., Lara P.N., et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 2014, 1-10.
114. Ji C., Zhang L., Cheng Y., Patel R., Wu H., Zhang Y., et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer Biol Ther 2014, 15(5):570-577.
115. Muders M.H. Neuropilin and neuropilin associated molecules as new molecular targets in pancreatic adenocarcinoma. Anticancer Agents Med Chem 2011, 11(June (5)):442-447.
116. Stanton M.J., Dutta S., Polavaram N.S., Roy S., Muders M.H., Datta K. Angiogenic growth factor axis in autophagy regulation. Autophagy 2013, 9(May (5)):789-790.
117. Stanton M.J., Dutta S., Zhang H., Polavaram N.S., Leontovich A.A., Hönscheid P., et al. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 2013, 73(January (1)):160-171.
118. Palacios F., Tushir J.S., Fujita Y., D'Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 2005, 25(January (1)):389-402.
119. Kurth I., Peitzsch C., Baumann M., Dubrovska A. The role of cancer stem cells in tumor radioresistance. Cancer Stem Cells [Internet] 2014 [cited 2014 Mar 31], 473-491. John Wiley & Sons, Available from: http://onlinelibrary.wiley.com/doi/10.1002/9781118356203.ch35/summary. V.K. Rajasekhar (Ed.).
120. Karamboulas C., Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013, 1830(February (2)):2481-2495.
121. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med Camb Mass 2011, 17(February (1-2)):103-112.
122. Wei Y., Jiang Y., Zou F., Liu Y., Wang S., Xu N., et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A 2013, 110(April (17)):6829-6834.
123. Liu Y.-P., Yang C.-J., Huang M.-S., Yeh C.-T., Wu A.T.H., Lee Y.-C., et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 2013, 73(January (1)):406-416.
124. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W., Chen Y.S., et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A 2012, 109(October (43)):E2939-E2948.
125. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(May (4)):704-715.
126. Xie M., Zhang L., He C., Xu F., Liu J., Hu Z., et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 2012, 113(May (5)):1501-1513.
127. Mäbert K., Cojoc M., Peitzsch C., Kurth I., Souchelnytskyi S., Dubrovska A. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 2014, (May (12)):1-19.
128. Fischer M., Yen W.-C., Kapoun A.M., Wang M., O'Young G., Lewicki J., et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011, 71(March (5)):1520-1525.
129. Borovski T., De Sousa E., Melo F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res 2011, 71(February (3)):634-639.
130. Korkaya H., Liu S., Wicha M.S. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res 2011, 17(19):6125-6129.
131. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012, 47(4):570-584.
132. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sánchez V., Sanders M., et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013, 123(March (3)):1348-1358.
133. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120(2):485-497.
134. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.-S., Azab F., Leleu X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113(April (18)):4341-4351.
135. Zeng Z., Samudio I.J., Munsell M., An J., Huang Z., Estey E., et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006, 5(December (12)):3113-3121.
136. Dubrovska A., Elliott J., Salamone R.J., Telegeev G.D., Stakhovsky A.E., Schepotin I.B., et al. CXCR4 expression in prostate cancer progenitor cells. PLoS ONE 2012, 7(2):e31226.
137. Kuonen F., Secondini C., Rüegg C. Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 2012, 18(19):5196-5202.
138. Chung Y.L., Jian J.J., Cheng S.H., Tsai S.Y., Chuang V.P., Soong T., et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12(9):2706-2715.
139. Sofia Vala I., Martins L.R., Imaizumi N., Nunes R.J., Rino J., Kuonen F., et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS ONE 2010, 5(June (6)):e11222.
140. Chapman J.D., Dugle D.L., Reuvers A.P., Meeker B.E., Borsa J. Letter studies on the radiosensitizing effect of oxygen in Chinese hamster cells. Int J Radiat Biol Relat Stud Phys Chem Med 1974, 26(October (4)):383-389.
141. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol R Coll Radiol Gt Br 2007, 19(August (6)):397-417.
142. Zannella V.E., Dal Pra A., Muaddi H., McKee T.D., Stapleton S., Sykes J., et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res Off J Am Assoc Cancer Res 2013, 19(December (24)):6741-6750.
143. Milosevic M., Warde P., Ménard C., Chung P., Toi A., Ishkanian A., et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2012, 18(April (7)):2108-2114.
144. Batchelor T.T., Gerstner E.R., Emblem K.E., Duda D.G., Kalpathy-Cramer J., Snuderl M., et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013, 110(47):19059-19064.
145. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140(January (1)):62-73.
146. Touil Y., Igoudjil W., Corvaisier M., Dessein A.-F., Vandomme J., Monté D., et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res Off J Am Assoc Cancer Res 2014, 20(February (4)):837-846.
147. Cho K.H., Choi M.J., Jeong K.J., Kim J.J., Hwang M.H., Shin S.C., et al. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate 2014, 74(May (5)):528-536.
148. Barriga E.H., Maxwell P.H., Reyes A.E., Mayor R. The hypoxia factor Hif-1α controls neural crest chemotaxis and epithelial to mesenchymal transition. J Cell Biol 2013, 201(May (5)):759-776.
149. Bao B., Ali S., Ahmad A., Azmi A.S., Li Y., Banerjee S., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS ONE 2012, 7(12):e50165.
150. Cojoc M., Peitzsch C., Trautmann F., Polishchuk L., Telegeev G.D., Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Oncotargets Ther 2013, 6:1347-1361.
151. Qiang L., Wu T., Zhang H.-W., Lu N., Hu R., Wang Y.-J., et al. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 2012, 19(February (2)):284-294.
152. Choi H., Chun Y.-S., Kim T.-Y., Park J.-W. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res 2010, 70(December (24)):10101-10111.
153. Bijlsma M.F., Groot A.P., Oduro J.P., Franken R.J., Schoenmakers S.H.H.F., Peppelenbosch M.P., et al. Hypoxia induces a hedgehog response mediated by HIF-1alpha. J Cell Mol Med 2009, 13(August (8B)):2053-2060.
154. Kaanders J.H.A.M., Bussink J., van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002, 3(December (12)):728-737.
155. Overgaard J., Hansen H.S., Specht L., Overgaard M., Grau C., Andersen E., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362(September (9388)):933-940.
156. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25(September (26)):4066-4074.
157. De Ridder M., Verellen D., Verovski V., Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide Biol Chem Off J Nitric Oxide Soc 2008, 19(September (2)):164-169.
158. Siemens D.R., Heaton J.P.W., Adams M.A., Kawakami J., Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74(October (4)):878-883.
159. Linkous A.G., Yazlovitskaya E.M. Novel radiosensitizing anticancer therapeutics. Anticancer Res 2012, 32(July (7)):2487-2499.
160. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8(July (7)):545-554.
161. Shigdar S., Lin J., Li Y., Yang C.J., Wei M., Zhus Y., et al. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Ther Deliv 2012, 3(February (2)):227-244.
162. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.-M., García-Echeverría C., et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci 2008, 30(December). pnas.0810956106.
163. Potiron V.A., Abderrahmani R., Abderrhamani R., Giang E., Chiavassa S., Di Tomaso E., et al. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013, 106(January (1)):138-146.
164. Chang L., Graham P.H., Hao J., Ni J., Bucci J., Cozzi P.J., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 2013, 4(October (10)):e875.
165. Karsten U., Goletz S. What makes cancer stem cell markers different?. Springerplus 2013, 2(December (1)):301.
166. Pecqueur C., Oliver L., Oizel K., Lalier L., Vallette F.M. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol 2013, 2013:805975.
167. Zieker D., Bühler S., Ustündag Z., Königsrainer I., Manncke S., Bajaeifer K., et al. Induction of tumor stem cell differentiation - novel strategy to overcome therapy resistance in gastric cancer. Langenbecks Arch Surg Dtsch Ges Für Chir 2013, 398(April (4)):603-608.
168. Piccirillo S.G.M., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444(December (7120)):761-765.
169. Reisfeld R.A. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 2013, 18(1-2):115-133.
170. Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25(January (1)):37-48.
171. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4(3):226-235.
172. Wang H.J., Guo Y.Q., Tan G., Dong L., Cheng L., Li K.J., et al. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 2013, 114(10):2248-2257.
173. Huang F.F., Wu D.S., Zhang L., Yu Y.H., Yuan X.Y., Li W.J., et al. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett 2013, 336(1):96-105.
174. Van den Broeck A., Gremeaux L., Topal B., Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 2012, 12:354.
175. Hu L., McArthur C., Jaffe R.B. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010, 102(8):1276-1283.
176. Nakanishi T., Chumsri S., Khakpour N., Brodie A.H., Leyland-Jones B., Hamburger A.W., et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 2010, 102(5):815-826.
177. Zhang S.N., Huang F.T., Huang Y.J., Zhong W., Yu Z. Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori 2010, 96(6):985-992.
178. Zhang G., Wang Z., Luo W., Jiao H., Wu J., Jiang C. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol Res Pract 2013, 2013:782581.
179. Hou H., Sun H., Lu P., Ge C., Zhang L., Li H., et al. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. Mol Cancer Ther 2013, 12(12):2874-2884.
180. Wang X., Liu Q., Hou B., Zhang W., Yan M., Jia H., et al. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS ONE 2013, 8(9):e73942.
181. Yashiro M., Nishii T., Hasegawa T., Matsuzaki T., Morisaki T., Fukuoka T., et al. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer 2013, 109(10):2619-2628.
182. Adhikari A.S., Agarwal N., Wood B.M., Porretta C., Ruiz B., Pochampally R.R., et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010, 70(11):4602-4612.
183. Jang J.Y., Kim M.K., Jeon Y.K., Joung Y.K., Park K.D., Kim C.W. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med 2012, 44(4):251-259.
184. Chua C., Zaiden N., Chong K.H., See S.J., Wong M.C., Ang B.T., et al. Characterization of a side population of astrocytoma cells in response to temozolomide. J Neurosurg 2008, 109(5):856-866.
185. Hämmerle B., Yañez Y., Palanca S., Cañete A., Burks D.J., Castel V., et al. Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS ONE 2013, 8(10):e76761.
186. Wouters J., Stas M., Gremeaux L., Govaere O., Van den Broeck A., Maes H., et al. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS ONE 2013, 8(10):e76550.
187. Liu P.P., Liao J., Tang Z.J., Wu W.J., Yang J., Zeng Z.L., et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 2014, 21(1):124-135.
188. Wang Y.C., Chao T.K., Chang C.C., Yo Y.T., Yu M.H., Lai H.C. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS ONE 2013, 8(9):e74538. 10.1371/journal.pone.0074538.
189. Zhao Y., Bao Q., Schwarz B., Zhao L., Mysliwietz J., Ellwart J., et al. Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases. Stem Cells Dev 2014, 23(2):180-192.
190. Yasuda K., Torigoe T., Morita R., Kuroda T., Takahashi A., Matsuzaki J., et al. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS ONE 2013, 8(8):e68187.
191. Huang B., Huang Y.J., Yao Z.J., Chen X., Guo S.J., Mao X.P., et al. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS ONE 2013, 8(7):e68293.
192. Wu C.P., Zhou L., Xie M., Du H.D., Tian J., Sun S., et al. Identification of cancer stem-like side population cells in purified primary cultured human laryngeal squamous cell carcinoma epithelia. PLoS ONE 2013, 8(6):e65750.
193. Lee H., Kim J.B., Park S.Y., Kim S.S., Kim H. Combination effect of paclitaxel and hyaluronic acid on cancer stem-like side population cells. J Biomed Nanotechnol 2013, 9(2):299-302.
194. Shishido Y., Ueno S., Yamazaki R., Nagaoka M., Matsuzaki T. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res 2013, 33(4):1379-1386.
195. Li R., Wu X., Wei H., Tian S. Characterization of side population cells isolated from the gastric cancer cell line SGC-7901. Oncol Lett 2013, 5(3):877-883.
196. Sobhan P.K., Seervi M., Joseph J., Chandrika B.B., Varghese S., Santhoshkumar T.R., et al. Identification of heat shock protein 90 inhibitors to sensitize drug resistant side population tumor cells using a cell based assay platform. Cancer Lett 2012, 317(1):78-88.
197. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70(20):8097-8107.
198. Singh A., Wu H., Zhang P., Happel C., Ma J., Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010, 9(8):2365-2376.
199. Chikazawa N., Tanaka H., Tasaka T., Nakamura M., Tanaka M., Onishi H., et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010, 30(June (6)):2041-2048.
200. Katayama R., Koike S., Sato S., Sugimoto Y., Tsuruo T., Fujita N. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci 2009, 100(11):2060-2068.
201. Kim S.K., Kim H., Lee D.H., Kim T.S., Kim T., Chung C., et al. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS ONE 2013, 8(10):e78130.
202. Liu J., Xiao Z., Wong S.K., Tin V.P., Ho K.Y., Wang J., et al. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget 2013, 4(10):1698-1711.
203. Corominas-Faja B., Oliveras-Ferraros C., Cuyàs E., Segura-Carretero A., Joven J., Martin-Castillo B., et al. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 2013, 12(21):3390-3404.
204. Schott A.F., Landis M.D., Dontu G., Griffith K.A., Layman R.M., Krop I., et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 2013, 19(6):1512-1524.
205. Nishikawa S., Konno M., Hamabe A., Hasegawa S., Kano Y., Ohta K., et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol 2013, 42(4):1437-1442.
206. Awad O., Yustein J.T., Shah P., Gul N., Katuri V., O'Neill A., et al. High; ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS ONE 2010, 5(11):e13943.
207. Schäfer A., Teufel J., Ringel F., Bettstetter M., Hoepner I., Rasper M., et al. Aldehyde dehydrogenase 1A1 - a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol 2012, 14(12):1452-1464.
208. Bertrand G., Maalouf M., Boivin A., Battiston-Montagne P., Beuve M., Levy A., et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev 2014, 10(1):114-126.
209. Mihatsch J., Toulany M., Bareiss P.M., Grimm S., Lengerke C., Kehlbach R., et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol 2011, 99(3):300-306.
210. Zhi Q.M., Chen X.H., Ji J., Zhang J.N., Li J.F., Cai Q., et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother 2011, 65(7):509-515.
211. Wang W.J., Wu S.P., Liu J.B., Shi Y.S., Huang X., Zhang Q.B., et al. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res 2013, 73(3):1219-1231.
212. Ropolo M., Daga A., Griffero F., Foresta M., Casartelli G., Zunino A., et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009, 7(3):383-392.
213. Facchino S., Abdouh M., Chatoo W., Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010, 30(30):10096-10111.
214. Desai A., Webb B., Gerson S.L. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiother Oncol 2014, 110(3):538-545.